Germany Drug Manufacturers - General news

21:05 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

20:34 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇩🇪 Germany

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

BRM mentioned

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

20:07 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇩🇪 Germany

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

LLY main company NOV mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

19:05 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Jim Cramer Highlights Arista Networks (ANET) Following Q2 Beat and 50% Rally

Arista Networks, Inc. (NYSE:ANET) posted $3.04 billion in total sales for Q2 2026, which represents a 37.7% year-over-year increase and beat Wall Street consensus estimates by $210 million. Non-GAAP earnings per share came in at $1.02, topping expectations by $0.13. The top-line expansion pulled …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +52.1%

18:20 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

17:54 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

LLY mentioned JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

17:52 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Jim Cramer Weighs In on Sentiment Shifts Driving Accenture and Cognizant Rallies

On Monday's CNBC Mad Money episode, host Jim Cramer examined the top-performing stocks in the S&P 500, focusing on the dramatic turnaround in IT consulting leaders Cognizant Technology Solutions Corporation (NASDAQ:CTSH) and Accenture plc (NYSE:ACN). Addressing how market sentiment shifted around the "AI displacement …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +52.1%

17:50 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak …

JNJ mentioned BRM mentioned

Sharemaestro market context Trend signal active 52 weeks +52.1%

17:45 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

17:12 11 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇩🇪 Germany

Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts …

RHO mentioned

Sharemaestro market context Price above Trend Line 52 weeks +44.8% · Next-week setup positive 61.8%

17:00 11 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

16:26 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇩🇪 Germany

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NOV mentioned

Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%

16:12 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇩🇪 Germany

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

LLY main company NOV mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

16:00 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...

This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up …

NOT mentioned

Sharemaestro market context Trend signal active 52 weeks +32.0% · Next-week setup positive 64.7%

15:30 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

RHO mentioned BAYN mentioned

Sharemaestro market context Price above Trend Line 52 weeks +44.8% · Next-week setup positive 61.8%

14:40 11 Aug 2026

seekingalpha.com Market update Provider-linked mention 🇩🇪 Germany

These stocks have some of Wall Street’s lowest short interest

[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares …

LLY mentioned JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

14:20 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇩🇪 Germany

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

AMG mentioned SNW mentioned

Sharemaestro market context Trend signal active 52 weeks +44.5%

14:12 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

LLY mentioned JNJ mentioned GIS mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

14:09 11 Aug 2026

finance.yahoo.com Capital return Provider-linked mention 🇩🇪 Germany

The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run

Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +52.1%

14:00 11 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇩🇪 Germany

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

JNJ mentioned GIS mentioned PFE mentioned

Sharemaestro market context Trend signal active 52 weeks +52.1%

14:00 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇩🇪 Germany

Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced …

GIS mentioned

Sharemaestro market context Price below Trend Line 52 weeks +18.2% · Next-week setup positive 57.6%

13:44 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇩🇪 Germany

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

LLY main company NOV mentioned

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

13:38 11 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

NOV main company

Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%

13:31 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.2%

12:43 11 Aug 2026

nasdaq.com Analyst action Main company 🇩🇪 Germany

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

NOV main company

Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%

12:03 11 Aug 2026

finance.yahoo.com Market update Main company 🇩🇪 Germany

Veeva Vault CRM Selected by Eli Lilly and Company

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

11:39 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

CEZ Raises 2026 Outlook as Nuclear Output and Power Prices Improve

Czech utility CEZ Group raised its full-year 2026 earnings forecast after reporting a 20% decline in first-half EBITDA as lower realized electricity prices weighed on its generation business. The company now expects full-year EBITDA of CZK 109 billion to CZK 114 billion, while adjusted …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

09:45 11 Aug 2026

finance.yahoo.com Guidance Provider-linked mention 🇩🇪 Germany

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

GIS mentioned

Sharemaestro market context Price below Trend Line 52 weeks +18.2% · Next-week setup positive 57.6%

08:36 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

New Strong Sell Stocks for August 11th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Buzzi S.p.A. BZZUF is a building materials company. The Zacks Consensus Estimate for its current year earnings has been revised 10.4% downward over the last 60 days. Group 1 Automotive, …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

08:30 11 Aug 2026

nasdaq.com Regulatory and legal Main company 🇩🇪 Germany

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +73.4% · Next-week setup positive 55.4%

07:57 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇩🇪 Germany

Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.

OSLO, Norway, August 11, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

06:43 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇩🇪 Germany

Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals

During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and …

BRM mentioned

Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 57.3%

06:00 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed

Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights – first half …

NOT mentioned

Sharemaestro market context Trend signal active 52 weeks +32.0% · Next-week setup positive 64.7%

02:04 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...

This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). …

BAYN mentioned

Sharemaestro market context Trend signal active 52 weeks +84.7%

02:03 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇩🇪 Germany

OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...

This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million …

NOT mentioned

Sharemaestro market context Trend signal active 52 weeks +32.0% · Next-week setup positive 64.7%

01:20 11 Aug 2026

finance.yahoo.com Earnings Main company 🇩🇪 Germany

What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders

In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +52.1%